Lauren Elaine Eggert, MD
Critical Care (Intensivists) · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 2 carriers
- Offices
- 4
Offices
4 locations · UCSF Medical Group Business Services · Regents of the University of California
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
4 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Eggert’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
4 of 4 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A148609 · Current
Licensed to practise in California · since 2017 · expires 2026-12-31 · Albert Einstein College of Medicine of Yeshiva University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$67,132
Medicare paid this office $67,132 for 417 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 96 | $34,139 | $181 |
| Short return visit (20+ min) | 58 | $6,011 | $75 |
| Return visit (30+ min) | 32 | $5,022 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,238 | $106 |
| Return visit (30+ min) | 29 | $2,898 | $83 |
See all 13 services
| Critical care, first 30-74 minutes | 96 | $34,139 | $181 |
| Short return visit (20+ min) | 58 | $6,011 | $75 |
| Return visit (30+ min) | 32 | $5,022 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,238 | $106 |
| Return visit (30+ min) | 29 | $2,898 | $83 |
| New patient visit (60+ min) | 15 | $1,956 | $130 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,706 | $155 |
| Critical care, each additional 30 minutes | 11 | $1,570 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $911 | $70 |
| Test to examine how well the lungs exchange gases | 93 | $696 | $7 |
| Test to measure expiratory airflow and volume | 82 | $592 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 61 | $508 | $8 |
| Test to determine lung volumes using sensors | 35 | $348 | $10 |
Who their Medicare patients are
417 Original Medicare patients in 2024. Average age 74 · Under 65 12% · 85 and older 13% · Women 56% · Also on Medicaid 29% · Health risk score 2.21. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 75% · COPD 40% · Coronary heart disease 36% · Diabetes 35% · Chronic kidney disease 32% · Heart failure 31% · Atrial fibrillation 29% · Depression 25% · Cancer 19% · Dementia 14% · Stroke 12%.
The office billed $521,950, Medicare allowed $87,328 and paid $67,132; for 823 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 417 | 823 | 74 | 2.21 | $521,950 | $67,132 |
| 2023 | 392 | 854 | 74 | 2.27 | $450,995 | $58,678 |
| 2022 | 384 | 774 | 74 | 2.29 | $604,426 | $78,594 |
| 2021 | 320 | 736 | 72 | 2.00 | $365,936 | $53,370 |
| 2020 | 99 | 192 | 72 | 2.02 | $154,094 | $19,868 |
| 2017 | 74 | 93 | 80 | 2.85 | $63,167 | $12,379 |
| 2016 | 148 | 201 | 80 | 2.21 | $135,515 | $28,041 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Critical care, first 30-74 minutes | 71 | $25,200 | $189 |
| Short return visit (20+ min) | 40 | $4,502 | $74 |
| Return visit (30+ min) | 21 | $3,335 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $3,291 | $110 |
| Return visit (30+ min) | 32 | $3,071 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,772 | $73 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,411 | $151 |
| Telehealth originating site facility fee | 51 | $1,958 | $21 |
| Long return visit (40+ min) | 15 | $1,824 | $122 |
| Critical care, each additional 30 minutes | 11 | $1,426 | $95 |
| Test to examine how well the lungs exchange gases | 108 | $805 | $7 |
| Test to measure expiratory airflow and volume | 89 | $611 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 70 | $572 | $8 |
| Test to determine lung volumes using sensors | 45 | $449 | $10 |
2022: 15 services
| Critical care, first 30-74 minutes | 94 | $39,055 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $6,577 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,284 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $3,978 | $65 |
| Short return visit (20+ min) | 28 | $3,818 | $78 |
| Return visit (30+ min) | 29 | $2,797 | $85 |
| Return visit (30+ min) | 15 | $2,379 | $113 |
| New patient visit (60+ min) | 14 | $2,364 | $169 |
| Telehealth originating site facility fee | 43 | $1,418 | $20 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,260 | $97 |
| Short return visit (20+ min) | 19 | $1,025 | $49 |
| Test to examine how well the lungs exchange gases | 38 | $318 | $8 |
| Test to measure expiratory airflow and volume | 36 | $279 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 24 | $226 | $9 |
| Test to determine lung volumes using sensors | 13 | $143 | $11 |
2021: 13 services
| Critical care, first 30-74 minutes | 56 | $22,815 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,184 | $88 |
| New patient visit (60+ min) | 15 | $2,874 | $192 |
| Short return visit (20+ min) | 25 | $2,751 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,232 | $66 |
| New patient visit (60+ min) | 11 | $1,999 | $182 |
| Short return visit (20+ min) | 17 | $1,454 | $61 |
| Return visit (30+ min) | 14 | $1,343 | $90 |
| Telehealth originating site facility fee | 38 | $1,286 | $21 |
| Test to examine how well the lungs exchange gases | 98 | $809 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 66 | $640 | $10 |
| Test to determine lung volumes using sensors | 49 | $547 | $11 |
| Test to measure expiratory airflow and volume | 65 | $496 | $8 |
2020: 3 services
| Critical care, first 30-74 minutes | 30 | $11,230 | $201 |
| Telehealth originating site facility fee | 12 | $288 | $22 |
| Test to examine how well the lungs exchange gases | 14 | $120 | $9 |
2017: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,435 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,992 | $95 |
2016: 3 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 107 | $19,905 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $4,429 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,082 | $65 |
Medicaid work
$5,871 in 2024
Medicaid paid $5,871 for 117 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 27 | $5,278 |
| Diffusing capacity | 53 | $290 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 22 | $167 |
| EVALUATION OF WHEEZING | 15 | $136 |
| 2024 | 117 | 4 | 22 | $5,871 |
| 2023 | 96 | 4 | 20 | $13,306 |
| 2022 | 27 | 2 | 15 | $131 |
| 2021 | 25 | 2 | 13 | $365 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 43 | $12,792 |
| Telehealth originating site facility fee | 12 | $306 |
| Diffusing capacity | 28 | $131 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 13 | $77 |
2022
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 15 | $68 |
| Diffusing capacity | 12 | $64 |
2021
| Telehealth originating site facility fee | 12 | $277 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 13 | $88 |
Drugs they prescribed that Part D paid
$483,408
Pharmacies billed $483,408 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 542) in 2024. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 0%.
192 generic and 350 brand-name prescriptions · $483,408 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xolair | 28 | $100,457 | $3,588 |
| Trelegy Ellipta | 112 | $85,986 | $768 |
| Fasenra | 14 | $73,476 | $5,248 |
| Dupixent | 17 | $69,859 | $4,109 |
| Nucala | 14 | $51,000 | $3,643 |
See all 16 drugs
| Xolair | 28 | $100,457 | $3,588 |
| Trelegy Ellipta | 112 | $85,986 | $768 |
| Fasenra | 14 | $73,476 | $5,248 |
| Dupixent | 17 | $69,859 | $4,109 |
| Nucala | 14 | $51,000 | $3,643 |
| Breztri Aerosphere | 28 | $18,191 | $650 |
| Breo Ellipta | 18 | $11,224 | $624 |
| Breyna | 20 | $6,250 | $313 |
| Symbicort | 18 | $5,927 | $329 |
| Advair Hfa | 18 | $5,773 | $321 |
| Wixela Inhub | 16 | $889 | $56 |
| Albuterol Sulfate Hfa | 25 | $670 | $27 |
| Montelukast | 31 | $306 | $10 |
| Fluticasone Propionate | 15 | $243 | $16 |
| Prednisone | 32 | $170 | $5 |
| Levocetirizine Dihydrochloride | 15 | $101 | $7 |
Year by year
| 2024 | 542 | 89 | 0% (0) | 65% | $483,408 |
| 2023 | 509 | 83 | 0% (0) | 71% | $435,946 |
| 2022 | 550 | 99 | None | 65% | $316,969 |
| 2021 | 321 | 63 | 0% (0) | 62% | $158,220 |
| 2020 | 96 | 23 | 0% (0) | 46% | $27,696 |
| 2017 | 34 | 13 | 0% (0) | None | $3,593 |
| 2016 | 600 | 62 | None | None | $29,506 |
| 2015 | 72 | 17 | 0% (0) | 17% | $3,912 |
| 2014 | 38 | 17 | None | None | $1,429 |
| 2013 | 22 | None | None | None | $1,779 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Xolair | 30 | $100,770 | $3,359 |
| Dupixent | 25 | $93,180 | $3,727 |
| Nucala | 19 | $73,014 | $3,843 |
| Trelegy Ellipta | 97 | $70,656 | $728 |
| Breztri Aerosphere | 34 | $23,117 | $680 |
| Symbicort | 42 | $16,977 | $404 |
| Flovent Hfa | 14 | $4,262 | $304 |
| Ventolin Hfa | 16 | $959 | $60 |
| Albuterol Sulfate Hfa | 19 | $458 | $24 |
| Azelastine | 13 | $255 | $20 |
| Prednisone | 40 | $217 | $5 |
| Montelukast | 22 | $184 | $8 |
| Azithromycin | 11 | $60 | $5 |
2022: 15 drugs
| Trelegy Ellipta | 102 | $77,353 | $758 |
| Dupixent | 16 | $54,495 | $3,406 |
| Nucala | 15 | $52,244 | $3,483 |
| Dupixent | 12 | $44,001 | $3,667 |
| Breztri Aerosphere | 31 | $20,010 | $645 |
| Symbicort | 34 | $13,126 | $386 |
| Breo Ellipta | 21 | $9,010 | $429 |
| Anoro Ellipta | 17 | $7,996 | $470 |
| Flovent Hfa | 25 | $6,657 | $266 |
| Budesonide-Formoterol | 11 | $4,439 | $404 |
| Wixela Inhub | 11 | $2,112 | $192 |
| Albuterol Sulfate Hfa | 36 | $1,857 | $52 |
| Fluticasone Propionate | 17 | $313 | $18 |
| Prednisone | 27 | $140 | $5 |
| Montelukast | 14 | $119 | $9 |
2021: 9 drugs
| Nucala | 12 | $41,150 | $3,429 |
| Trelegy Ellipta | 30 | $18,633 | $621 |
| Symbicort | 33 | $15,190 | $460 |
| Anoro Ellipta | 25 | $11,336 | $453 |
| Flovent Hfa | 19 | $5,006 | $263 |
| Albuterol Sulfate Hfa | 13 | $673 | $52 |
| Prednisone | 27 | $162 | $6 |
| Montelukast | 14 | $113 | $8 |
| Pantoprazole | 11 | $105 | $10 |
2016: 18 drugs
| Ventolin Hfa | 15 | $756 | $50 |
| Oxybutynin Chloride Er | 11 | $443 | $40 |
| Polyethylene Glycol 3350 | 15 | $433 | $29 |
| Valsartan | 14 | $395 | $28 |
| Atorvastatin | 37 | $377 | $10 |
| Metoprolol | 14 | $258 | $18 |
| Hydralazine | 17 | $234 | $14 |
| Finasteride | 14 | $153 | $11 |
| Gabapentin | 12 | $136 | $11 |
| Fluticasone Propionate | 21 | $135 | $6 |
| Simvastatin | 21 | $108 | $5 |
| Amlodipine Besylate | 28 | $82 | $3 |
| Lisinopril | 22 | $81 | $4 |
| Losartan | 24 | $81 | $3 |
| Metformin | 14 | $75 | $5 |
| Metoprolol | 19 | $58 | $3 |
| Hydrochlorothiazide | 22 | $37 | $2 |
| Furosemide | 20 | $32 | $2 |
Money from drug and device companies
$33,951 in 2025
| 2025 | 8 | 39 | $31,315 | $33,951 |
| 2024 | 5 | 19 | $14,099 | $15,880 |
| 2023 | 2 | 6 | $6,020 | $6,180 |
| 2022 | 1 | 2 | None | $76 |
| 2021 | 1 | 1 | None | $17 |
| 2019 | 1 | 1 | None | $100 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Nucala | $23,749 | 15 payments
|
| Genentech USA | Xolair | $5,631 | 8 payments
|
| Regeneron Healthcare Solutions | Dupixent | $2,393 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $2,025 | 4 payments
|
| Merck Sharp & Dohme | Winrevair | $75 | 1 payment
|
| Amgen | None | $34 | 1 payment
|
See all 39 published payments
| GlaxoSmithKline | Paid to speak or teach · 2025-12-04 | None | $2,600 |
| GlaxoSmithKline | Paid to speak or teach · 2025-11-25 | None | $1,300 |
| GlaxoSmithKline | Meals · 2025-11-19 | None | $125 |
| GlaxoSmithKline | Paid to speak or teach · 2025-10-23 | Nucala | $650 |
| GlaxoSmithKline | Paid to speak or teach · 2025-10-17 | None | $975 |
| GlaxoSmithKline | Consulting · 2025-09-18 | Nucala | $1,950 |
| GlaxoSmithKline | Consulting · 2025-09-15 | Nucala | $1,950 |
| Regeneron Healthcare Solutions | Meals · 2025-09-10 | Dupixent | $135 |
| Insmed | Education · 2025-09-09 | Brinsupri | $17 |
| Amgen | Education · 2025-08-15 | None | $34 |
| GlaxoSmithKline | Consulting · 2025-06-25 | None | $13,000 |
| Genentech USA | Travel · 2025-06-07 | None | $76 |
| Genentech USA | Travel · 2025-06-07 | None | $272 |
| Genentech USA | Meals · 2025-06-07 | None | $106 |
| Genentech USA | Meals · 2025-06-07 | None | $63 |
| Genentech USA | Meals · 2025-06-07 | None | $79 |
| Genentech USA | Meals · 2025-06-07 | None | $93 |
| Genentech USA | Consulting · 2025-06-07 | None | $4,888 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-06-02 | Fasenra | $1,860 |
| Regeneron Healthcare Solutions | Meals · 2025-05-21 | Dupixent | $90 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-20 | None | $39 |
| Genentech USA | Meals · 2025-05-20 | Xolair | $54 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-18 | None | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-18 | Fasenra | $110 |
| GlaxoSmithKline | Meals · 2025-05-17 | None | $12 |
| GlaxoSmithKline | Meals · 2025-05-17 | None | $62 |
| GlaxoSmithKline | Meals · 2025-05-17 | None | $108 |
| GlaxoSmithKline | Meals · 2025-05-17 | None | $104 |
| GlaxoSmithKline | Meals · 2025-05-17 | None | $120 |
| GlaxoSmithKline | Travel · 2025-05-16 | None | $610 |
| GlaxoSmithKline | Travel · 2025-05-16 | None | $182 |
| Merck Sharp & Dohme | Meals · 2025-03-20 | Winrevair | $75 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-07 | Dupixent | $612 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-07 | Dupixent | $612 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-07 | Dupixent | $306 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-07 | Dupixent | $306 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-07 | Dupixent | $306 |
| Regeneron Healthcare Solutions | Meals · 2025-03-06 | Dupixent | $27 |
| Genzyme | Meals · 2025-02-06 | Wayrilz | $27 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $15,880
| Genzyme | Dupixent | $11,378 | 8 payments
|
| GlaxoSmithKline | Nucala | $2,318 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $1,763 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $391 | 6 payments
|
| Amgen | Tezspire | $30 | 1 payment
|
2023: $6,180
| AstraZeneca Pharmaceuticals LP | None | $4,418 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $1,762 | 5 payments
|
2022: $76
| Regeneron Healthcare Solutions | Dupixent | $76 | 2 payments
|
2021: $17
| Octapharma USA | Cutaquig | $17 | 1 payment
|
2019: $100
| Genentech USA | Esbriet | $100 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis · 2022 | Their institution | $19,804 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis · 2023 | Their institution | $6,144 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1366784274
- Licence
- CA A148609, NY 278223California A148609: Current · expires 2026-12-31
- Trained
- Albert Einstein College of Medicine of Yeshiva University, 2013
- Group
- UCSF Medical Group Business Services · Regents of the University of California
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X)
- Mailing address
- 400 Parnassus Ave, San Francisco, CA, 94143
- NPI first listed
- 2013-03-19
- NPI last updated
- 2025-07-09
- NPI record certified
- 2025-07-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Community Dr, Manhasset, NY, 11030